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Demonstration of Epitope-Spreading Phenomena
in Bullous Pemphigoid: Results of a Prospective
Multicenter Study
Giovanni Di Zenzo1, Sybille Thoma-Uszynski2, Valentina Calabresi1, Lionel Fontao3, Silke C. Hofmann4,
Jean-Philippe Lacour5, Francesco Sera6, Leena Bruckner-Tuderman4, Giovanna Zambruno1, Luca Borradori7
and Michael Hertl8,2
Bullous pemphigoid (BP), the most common autoimmune subepidermal bullous disease, is associated with an
autoantibody response to BP180 and BP230, two components of junctional adhesion complexes in human skin
promoting dermo–epidermal cohesion. Retrospective analyses demonstrated that these autoantigens harbor
several epitopes targeted by autoaggressive B and T cells. The aim of this prospective multicenter study was to
assess the evolution of IgG autoantibodies in 35 BP patients over a 12-month observation period. Epitope-
spreading (ES) events were detected in 17 of 35 BP patients (49%). They preferentially occurred in an early stage
of the disease and were significantly related to disease severity at diagnosis. Moreover, in three patients,
spreading of IgG reactivity to intracellular epitopes of BP180 and BP230 was preceded by recognition of the
BP180 ectodomain. Finally, IgG reactivity with extracellular epitopes of BP180 and intracellular epitopes of BP230
correlated with the severity of BP in disease course. These findings support the idea that IgG recognition of the
BP180 ectodomain is an early and crucial event in BP disease, followed by variable intra- and intermolecular
ES events, which likely shape the individual course of BP.
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INTRODUCTION
Bullous pemphigoid (BP) is the most common autoimmune
bullous skin disease associated with a humoral immune
response against components of the skin basement mem-
brane zone, i.e., BP180 (collagen XVII, BP antigen 2) and
BP230 (BP antigen 1-e; Labib et al., 1986; Stanley et al.,
1988). BP180 is a type II transmembrane protein, which
consists of a globular cytoplasmic domain and a large
extracellular region containing 15 collagenous domains
(Giudice et al., 1992; Hirako et al., 1996). BP230 is a
cytoplasmic plakin protein family member with a central rod
flanked by globular end domains (Stanley et al., 1988; Green
et al., 1992). Most BP patients have IgG autoantibody and
T-cell response directed against an immunodominant extra-
cellular domain of BP180, termed BP180-NC16A (Zillikens
et al., 1997; Nishie et al., 2010). The pathogenic relevance of
immunological recognition of BP180-NC16A is supported by
the observation that experimental transfer of IgG against this
domain into neonatal mice and hamsters elicits subepidermal
blisters like those seen in patients with BP (Liu et al., 1993;
Yamamoto et al., 2002). In addition, it has been shown that
injection of IgG from BP patients’ sera into BP180-humanized
mice produces immunopathological alterations resembling
those seen in BP (Nishie et al., 2007). Moreover, inactivation
of BP180-NC16A-reactive IgG with a recombinant NC16A
decoy peptide blocks the pathogenic activity of IgG from the
BP sera in vivo. Finally, an active BP mouse model has been
recently established by transferring into Rag-2(/)/BP180-
humanized mice splenocytes from wild-type mice grafted
with human BP180-transgenic mouse skin (Ujiie et al., 2010).
Retrospective analyses in BP patients demonstrated that, in
addition to the BP180-NC16A domain, there are several
epitopes of BP180 and BP230 that are targeted by both
autoaggressive B and T cells (Tanaka et al., 1991; Murakami
et al., 1998; Perriard et al., 1999; Skaria et al., 2000; Di
Zenzo et al., 2004; Mariotti et al., 2004; Thoma-Uszynski
et al., 2006).
The current model of chronic autoimmune diseases
predicts that ‘‘dominant’’ self-epitopes induce the inflamma-
tory cascade and tissue damage in the target organ. Recruitment
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and activation of autoreactive T lymphocytes specific for
‘‘secondary’’ epitopes of the nominal autoantigen or on
distinct self-proteins subsequently contribute to disease
course (Chan et al., 1998; Vanderlugt and Miller, 2002).
This phenomenon is called epitope spreading (ES). There is
growing evidence that inter- and intramolecular ES events are
not simply an epiphenomen but are critical in the evolution
and progression of autoimmune diseases (Naserke et al.,
1998; Vader et al., 2002; Arbuckle et al., 2003; Di Lorenzo
et al., 2007; Griffiths, 2008).
The dynamics of IgG reactivity has been recently analyzed
in a mouse model of BP, in which grafting of skin obtained
from transgenic mice expressing human BP180 on wild-type
mice resulted in triggering of an immune response to BP180.
In this model, IgG reactivity with extracellular epitopes
preceded IgG recognition of intracellular domain. Appear-
ance of IgG autoantibodies directed against intracellular
epitopes correlated with the development of graft loss (Di
Zenzo et al., 2010). A recent study that utilized a vast array of
BP230 and BP180 peptides strongly suggested that BP
patients have a specific IgG autoantibody profile, including
IgG recognition of intracellular epitopes, which is detectable
already at an early stage of the disease (Di Zenzo et al.,
2008). However, it is still not well understood whether IgG
reactivity with BP180 and BP230 spreads toward other
epitopes during the course of BP and whether recognition
of different epitopes is related to disease severity.
In this multicenter prospective study, we have assessed the
profile of IgG autoantibody response to distinct BP180 and
BP230 epitopes during the clinical course of 35 BP patients.
We have been able to detect ES events in up to 50% of the
patients. Specifically, we observed intramolecular ES events
consisting of early IgG reactivity with extracellular epitopes,
which was followed by IgG reactivity with intracellular
epitopes of BP180. Moreover, we also detected intermole-
cular ES consisting of an initial IgG reactivity with BP180
epitopes, with subsequent recognition of BP230 epitopes.
Finally, we found that IgG reactivity with extracellular epi-
topes of BP180 and intracellular epitopes of BP230 correlated
with the severity of BP during disease course, whereas IgG
recognition of intracellular epitopes of BP180 did not.
RESULTS
ES in the BP patients
This prospective study was designed to characterize and
correlate clinical and immunological parameters of BP
patients at the time of diagnosis and during disease course.
Therefore, we tested IgG reactivity against BP180 and BP230
recombinants (Figure 1) by different approaches before
treatment, as described elsewhere (Di Zenzo et al., 2008),
as well as during the course of the disease. Thirty-five BP
patients gave consent to be included in the follow-up study,
and the dynamics of the humoral response over a 12-month
period was investigated (Supplementary Table S1 online).
On performing ELISA, 17 of 35 (49%) BP patients were
found to have developed IgG reactivity with epitopes
that were not recognized at the time of first diagnosis
(Table 1). In contrast, 51% of the studied BP patients did not
show a shifted recognition of BP180 and BP230 epitopes
(Supplementary Table S2 online). All the 17 patients, in
whom ES occurred, had IgG reactivity with one or more
BP180 epitopes at the time of diagnosis, whereas 12 of 17 BP
(71%) patients showed IgG reactivity with BP230 epitopes. In
17 of the studied patients, we observed 24 different ES events
(considering as the same event the targeting of overlapping
recombinants): in 12 of these cases, ES events involved extra-
cellular epitopes and in the remaining 12 cases, intracellular
ones (Table 1). In particular, ES events involved epitopes of:
(1) the BP180 intracellular domain (5 of 24); (2) the mid-
portion of the BP180 ectodomain (6/24); (3) the BP180
COOH-terminal region (4/24); and (4) the NH2 and COOH
termini of BP230 (7/24). Noteworthy, ES events targeting
epitopes of BP180-NC16A were observed in two patients.
In contrast, patients who recognized BP180-NC16A at
diagnosis showed ES events involving extracellular (BP180;
n-8) and intracellular (BP180 and BP230; n-7) epitopes.
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Figure 1. Bullous pemphigoid (BP)180 and BP230 recombinant proteins.
(a) Schematic representation of BP180, a type II transmembrane protein
containing a globular intracellular domain and an extracellular domain
with 15 interrupted collagenous regions. (b) Schematic representation of
BP230, an intracellular hemidesmosomal component that consists of
a central rod flanked by globular end domains. The nomenclature of the
recombinant BP180 and BP230 fusion proteins, which are either expressed
prokaryotically (P-) or eukaryotically (E-), follows the amino-acid residues
(AA) of the reference protein. Linear IgA disease-1 (LAD-1) represents the
shed ectodomain of BP180 that was prepared from conditioned keratinocyte
medium and not a fragment produced as recombinant protein.
ECD, extracellular domain; ICD, intracellular domain.
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Table 1. Epitope spreading in 17 BP patients with IgG reactivity against BP180 and/or BP230
Patient Months 
BP1801 0132PB 
P      
151  
P     
176  
P      
316 
E      
467 
P      
490  
E      
490 
E      
485 
E     
809 
P       
1080 
E       
1048 
P       
1331  
E       
1352 
E    
1
E       
1881 
E       
2077 
A01 0       
1       
A11 0             
1             
A12 
0           
1           
6       
12               
A17 
0       
1       
6           
12           
B01 
0           
1             
3             
6             
12         
B06 
0      
1      
6      
12    
C01 
0    
1    
3R      
C03 
0       
1       
3       
6       
12         
C08 
0       
1           
6               
12             
C09 
0     
1           
6R       
C10 
0     
1     
6         
12       
C12 
0       
1     
6           
12           
C15 
0    
1    
3    
6    
12    
C17 
0       
3       
6    
12       
C19 
0           
1           
3         
6    
12           
E09 0             
1         
E11 
0    
1
6    
Abbreviations: AA, amino acid; BP, bullous pemphigoid, E, eukaryotically; ES, epitope spreading; P, prokaryotically; R, relapse.
1IgG reactivity against defined BP180 and/or BP230 recombinants is shown as gray boxes. ES is indicated in black. AA sequences of the recombinant
proteins are shown in Figure 1.
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Interestingly, most of the BP patients showed IgG reactivity
with BP180-NC16A and additional epitopes, whereas the
sera of three BP180-NC16A-negative BP patients (A12, B04,
and E17) recognized other BP180 and BP230 epitopes at
diagnosis (Supplementary Table S2 online).
Noteworthy, several patients showed IgA reactivity
with linear IgA disease-1 (LAD-1) at baseline as detected by
immunoblotting (11/35). In four BP patients (A01, C11, D03,
and E17), IgG reactivity with BP180 and BP230 at time of
diagnosis further spread to include IgA reactivity against
LAD-1 within 1 to 12 months after diagnosis (Supplementary
Table S2 online).
In three patients, IgG reactivity against the BP180 ectodomain
precedes recognition of intracellular epitopes
In three BP patients (A11, B01, and C19), IgG reactivity was
first specifically directed against the BP180 ectodomain,
which was followed by the development of a reactivity
with intracellular epitopes of BP180 and BP230 (Figure 2,
Supplementary Table S3 online). Initial IgG recognition of
intracellular epitopes with subsequent appearance of reac-
tivity with extracellular epitopes was never observed in the
course of the disease.
Intermolecular IgG reactivity spreading from BP180 to BP230
epitopes
Most ES events during the course of BP occurred intramole-
cularly, i.e., IgG autoantibodies of BP180, and in four cases
of BP230 epitopes (B06, C09, C12, and C15; Table 1).
Intermolecular ES was detected in 3 of 17 BP cases (A11,
C09, and C19; Table 1). Noteworthy, the IgG response was
first directed against BP180 and subsequently targeted BP230
epitopes, whereas IgG recognition of BP230 epitopes never
preceded that of BP180 epitopes (Table 1).
T-cell recognition of BP180 and BP230
We also investigated the dynamics of T-cell responses against
BP180 and BP230 recombinants during the course of
Intracellular
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COOHNH
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COOH
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Mo 1
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Figure 2. IgG recognition of the bullous pemphigoid (BP)180 ectodomain precedes reactivity against intracellular BP180 epitopes. Schematic representation
of the IgG autoantibody reactivity of three bullous pemphigoid (BP) patients (A11, B01, and C19) against intracellular and extracellular domains of BP180
and intracellular epitopes of BP230 during the course of the disease. The IgG autoantibody profile at different time points (expressed in months) is shown.
The targeted regions are highlighted as black bars. Secondary epitopes that arose as a consequence of epitope spreading are circled.
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the disease in nine BP patients. Five of nine BP patients
(A08, A11, A12, D02, and D11) showed a proliferative T-cell
response against BP180 and/or BP230 before treatment
(Table 2). Two of the five BP patients (A11 and D11) showed
ES events. In particular, in one patient (A11), T cell-reactivity
was initially directed against epitopes of the BP180 ectodo-
main and later on also involved the COOH-terminal region of
BP230 (Table 2). The second BP patient (D11) first showed
T-cell reactivity against BP180-NC16A, which shifted later on
toward T-cell recognition of the mid-portion and COOH-
terminal region of BP180 (Table 2). In the majority of the BP
patients, autoreactive B and T cells showed a similar epitope
profile during the disease course (Supplementary Table S4
online). In some patients, T-cell reactivity against the BP
recombinants was strongly impaired by treatment with
systemic glucocorticoids (Table 2).
ES events preferentially occur at an early stage of BP and are
related to clinical activity and severity
Incidence of ES events was more frequent during the first
3 months after diagnosis of BP (incidence¼0.26 person-
month) than at later observation periods (i.e., 6–12 months;
incidence¼ 0.07 person-month; P¼0.0013; (Figure 3a),
strongly suggesting that ES events are an early event in BP.
An association study aimed at determining whether specific
clinical and immunological features of BP at the time of first
diagnosis were related to ES events did not reveal a significant
association between ES and age, sex, mucosal involvement,
pruritus intensity, duration and extent of BP. There was also
no significant association between ES events and IgG reacti-
vity by ELISA and immunoblotting against distinct single
or grouped BP180 and/or BP230 epitopes. Of note, the
Table 2. Shifted T-cell recognition of BP180 and
BP230 in five of nine patients with BP
Patient Months  
BP1801 BP2301 
E      
467 
E      
490 
E      
485 
E     
809 
E      
1048 
E       
1352 
E    
1
E       
1881 
E       
2077 
A08 
0
    
1     
6
12
A11 0             1     
          
A12 
0
            
1
                
6
12
              
D02 
0
    
1       
        
6
        
12     
D11 
0
1
      
6
        
Abbreviations: AA, amino acid; BP, bullous pemphigoid, E-, eukaryoti-
cally; ES, epitope spreading; P-, prokaryotically; SI, stimulation index.
1Significant T-cell reactivity against defined BP180 and/or BP230
recombinants is shown as gray boxes. ES is indicated in black. AA
sequences of the recombinant proteins are shown in Figure 1.
Proliferative T-cell responses were defined by an SI (ratio of
[3H]thymidine uptake in T-cell cultures with/without Ag) X2.0.
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Figure 3. Epitope-spreading (ES) events preferentially occur early on and are
correlated with the clinical activity and severity of bullous pemphigoid.
(a) The incidence of ES events was significantly (P¼ 0.0013) different between
months 1–3 (incidence¼0.26 person-month, 95% confidence interval
(CI; 0.12; 0.48)) versus months 6–12 (incidence¼ 0.07 person-month,
95% CI (0.03; 0.12)). (b) ES events assessed by ELISA correlated with disease
severity (P¼ 0.013). Error bars show mean and±SE of disease severity in
patients with and without ES. (c) ES phenomena assessed by ELISA appeared
to be associated with disease activity, which was evaluated as the number of
new blisters during two consecutive days (P¼ 0.034). A bar plot shows the
ES risk (±SE) according to disease activity. When pairwise comparisons
were considered, a difference for ES risk was observed between absence of
blisters andX3 blisters (P¼ 0.014). The association was statistically significant
after taking into account Bonferroni correction for multiple comparisons.
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occurrence of ES events appeared to be significantly related
to the severity (P¼0.013) and clinical activity (P¼0.014) of
BP at the time of diagnosis (Figure 3b and c). Finally, during
disease course in a given BP patient, the level of IgG
reactivity against epitopes targeted by ES decreased more
rapidly than that against epitopes already recognized at
diagnosis (Supplementary Table S5 online).
IgG reactivity with the BP180 ectodomain but not with
intracellular epitopes of BP180 is related to the severity of BP
The present prospective study demonstrates a significant
relationship between the extent of IgG autoantibody reacti-
vity and the clinical severity of BP. On the basis of multiple
comparison analyses, there was a significant correlation of
disease severity with IgG reactivity against (1) BP180-NC16A
(recombinants E-467, E-490, and P-490); (2) the entire BP180
ectodomain (E-485); (3) COOH-terminal regions of the
BP180 ectodomain (E-1048 and E-1352); and (4) distinct
BP230 domains (E-1 and E-1881; Figure 4). In contrast, IgG
reactivity against intracellular BP180 epitopes (P-151, P-176,
and P-316) and the mid-portion (E-809 and P-1080) of the
BP180 ectodomain was not significantly related to disease
severity (Figure 4).
DISCUSSION
The present prospective multicenter study shows for the first
time that ES occurs early on in BP and is associated with a
more severe disease at diagnosis. Moreover, in three patients,
spreading of IgG reactivity to intracellular epitopes followed
IgG recognition directed against the BP180 ectodomain.
Moreover, this study shows that IgG reactivity with BP230
and extracellular, but not intracellular, epitopes of BP180
correlates with the severity of BP.
There is ample evidence obtained from studies in distinct
autoimmune diseases indicating a crucial role of ES during
the early stage of disease development (Brooks-Worrell
et al., 2001; Matsumoto et al., 2007; Poole et al., 2009).
The current model of autoimmune disease predicts that the
initial reactivity with the BP180 ectodomain induces tissue
damage that subsequently leads to disease progression
associated with further IgG recognition of intracellular
epitopes. In particular, we have previously demonstrated
that in BP, IgG binding to intracellular epitopes of BP180 and/
or BP230 is detectable early in disease course (Thoma-
Uszynski et al., 2004; Di Zenzo et al., 2004, 2007, 2008). In
line with these data, the present study shows that (1) at
diagnosis, almost all BP patients (34/35; 97%) presented IgG
reactivity with the BP180 ectodomain, whereas 27 of 35
patients (69%) had IgG against intracellular epitope(s) (BP180
intracellular domain and/or BP230); (2) whereas only one BP
patient serum (B04) exclusively bound to intracellular epi-
topes, eight patients (23%; A11, A19, B01, C02, C19, E09,
E11, and E17) presented exclusive recognition of BP180
ectodomain at diagnosis; (3) in 18/35 BP patients, IgG
recognition of multiple extracellular and intracellular epi-
topes was already detected at diagnosis and did not evolve
with ES; and (4) when ES occurred (17/35 patients), it was
preferentially an early event in the disease course. Altogether,
these findings indicate the idea that ES can occur also before
the development of overt clinical manifestations of BP.
The dynamics of T-cell responses against BP180 and
BP230 during the course of the disease were also investi-
gated in selected BP patients. The data show that in two of
five BP patients the proliferative T-cell response, which was
initially directed against epitopes of the BP180 ectodomain,
subsequently involved epitopes within BP230 or BP180
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Figure 4. IgG reactivity against bullous pemphigoid (BP)230 and BP180
extracellular, but not intracellular, epitopes relates to the clinical severity
of BP. Levels of IgG against: (a) BP230 (E-1); (b) the NH2-terminal (E-490);
and (c) the COOH-terminal region of the BP180 ectodomain (E-1048)
paralleled the mean decrease of disease severity, whereas mean IgG levels
against (d) the intracellular domain of BP180 (P-176) did not. Disease severity
and serum IgG reactivity, expressed as pemphigoid index value (PIV),
are shown as filled circles and squares, respectively. Error bars indicate
mean±SE. A longitudinal analysis (subject as fixed effect) conducted
considering time points at months 0, 1, 6, and 12 is shown in tables on
the right side of the figure. The associations that proved statistically
significant after multiple comparison analyses (in bold) had a Pp0.003.
ECD, extracellular domain; ICD, intracellular domain.
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ectodomain. Noteworthy, in one of these two patients (A11),
both B- and T-cell reactivity with the BP180 ectodomain
was initially found, which subsequently spread involving
BP230 as well. In addition, the comparison of B- with T-cell
reactivity during disease course showed a similar epitope
profile. These preliminary data support the relevance of T–B
cooperation and possible interplay in the ES process.
A technical limitation in interpreting the present ex vivo
T-cell proliferative responses to BP180 and BP230 was
the significant impairment of this assay by systemically
applied glucocorticoids, which are therapeutic mainstay in
BP. In contrast, systemic glucocorticoid treatment had a more
delayed inhibitory effect on serum IgG autoantibodies in the
studied BP patients.
The different patterns of epitope recognition/spreading
presumably shape the individual course of BP. Along this
line, we have investigated a possible relationship between ES
events and the clinical severity of BP. Interestingly, there was
a significant relation between the occurrence of ES and
both severity and clinical activity of BP at the time of first
diagnosis. On the other hand, with the exception of two BP
patients who showed an ES event during a relapse, we could
not observe a significant association between ES and severity
or remission during disease course. Evidences from animal
models of autoimmune diseases indicate that ES may be due
to the activation and recruitment of autoreactive T lympho-
cytes specific for epitopes that are distinct from the disease-
inducing epitope. In this context, it is possible that during the
disease course under immunosuppressive therapy, activation
and recruitment of T and B cells are impaired, leading to a
reduction of further ES events.
Several retrospective studies reported a direct correlation
between the levels of anti-BP180-NC16A IgG autoantibodies
and BP severity (Haase et al., 1998; Schmidt et al., 2000;
Hofmann et al., 2002). We have previously found a
significant relation between clinical severity of BP at
diagnosis and the levels of IgG reactivity with the NH2-
and COOH-terminal regions of the BP180 ectodomain (Di
Zenzo et al., 2008). In the present prospective study, IgG
levels against the extracellular but not the intracellular
domain of BP180 were related to the severity of BP.
Specifically, a significant relation between clinical activity
in disease course and reactivity to the NC16A domain and
COOH-terminal region of the BP180 ectodomain was found.
Furthermore, in line with a recent study (Charneux et al.,
2011), we have found that IgG levels against all the fragments
comprising the BP180-NC16A domain were much higher
than those measured for other epitopes of BP180 and BP230
(not shown). Finally, two of three BP180-NC16A-negative
BP patients (A12 and E17) at diagnosis showed IgG reac-
tivity with the COOH-terminal region of the BP180.
Altogether, these findings extend previous observations and
provide additional support to the idea that IgG autoanti-
bodies against the BP180-NC16A domain and the COOH-
terminal region of BP180 have a central role in the
pathogenesis of BP.
It is still unclear as to whether IgG autoantibodies to
BP230 are critical in the pathogenesis of BP. In the present
study, IgG reactivity against the cytoplasmic BP230 appeared
to be related to the severity of BP. A possible pathogenic role
of anti-BP230 IgG has been strongly suggested by the follow-
ing observations: (1) immunization of rabbits with BP230-
derived peptides appeared to increase the local inflammatory
response following epidermal damage (Hall et al., 1993) and
(2) IgG antibodies against specific portions of BP230 were
able to induce subepidermal blister formation (Kiss et al.,
2005). Additional support for a possible pathogenic role of
anti-BP230 IgG is provided by the reported direct relationship
between clinical severity of BP and IgG reactivity against
BP230 (Yoshida et al., 2006). In this context, it should be
noted that in the present study, two of three BP180-NC16A-
negative sera (A12 and B04) bound to BP230 epitopes at
time of initial diagnosis. Hence, it is conceivable that, at least
in a subset of patients, an autoantibody response to BP230
contributes to the pathogenesis of BP, e.g., by interfering with
BP230 binding to keratin intermediate filaments, and thus
leading to a loss of adhesion at the dermal–epidermal
junction (Skaria et al., 2000). In fact, several experimental
data suggest an involvement of intracellular antigens in the
development of autoimmune diseases. In particular, it has
been reported that penetration of mature autoantibodies
into living cells might participate in disease pathogenesis
(Ruiz-Argu¨elles et al., 2003).
In the majority of the patients, ES events occurred
intramolecularly mainly involving IgG responses to BP180.
Intermolecular ES was detected in three BP patients in whom
IgG autoantibodies first targeted the BP180 ectodomain and
only subsequently recognized intracellular epitopes of BP230
and in one case also of BP180. On the other hand, IgG
recognition of the cytoplasmic BP230 autoantigen never
preceded reactivity against BP180. IgG spreading from BP180
to BP230 might be attributed to the physical interaction
between the NH2-terminal portions of BP230 and BP180
(Borradori et al., 1998). These findings are in line with a
previous study aimed at investigating the dynamics of the IgG
response against human BP180 in a mouse model, in which
transgenic mouse skin expressing human BP180 was grafted
on wild-type animals (Di Zenzo et al., 2010). These mice
developed first IgG against extracellular BP180 epitopes
and thereafter IgG binding to intracellular epitopes. These
findings are also in keeping with the current model of
autoimmune disease that predicts an initial involvement of an
extracellular immunodominant epitope (i.e. BP180 ectodo-
main), inducing tissue damage that eventually leads to
disease progression associated with further IgG recognition
of intracellular epitopes.
As for IgA response, in all four BP patients in whom IgG
reactivity with BP180 and BP230 spread toward an
IgA reactivity with LAD-1, the disease went concomitantly
into remission. In addition, no significant association
was detected between IgA reactivity and any clinical
and immunological features, including disease severity and
duration, mucosal lesions, and ES events (data not shown).
These preliminary observations suggest a rather limited
pathogenic role of IgA autoantibodies, which, however,
remains to be further elucidated.
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The sequential development of IgG reactivity with
different epitopes and antigens during the course of the
disease could represent an obstacle to the application of
therapeutic approaches based on decoy peptides, tolerance
inducing peptides, or antibody-specific immunoadsorption.
In this context, the observation that the levels of IgG against
epitopes targeted by ES decreased more rapidly than those
against epitopes recognized at diagnosis could be of interest.
In conclusion, our study provides for the first time a
comprehensive and prospective characterization of the
evolution of humoral immune responses in BP patients.
Altogether, our findings lend support to the concept that IgG
recognition of the BP180 ectodomain is an early and crucial
event in BP.
MATERIALS AND METHODS
Prospective multicenter observational study in BP
Thirty-five BP patients were recruited in a prospective multicenter
study involving five European centers (Departments of Dermatology
in Rome, Geneva, Freiburg, Erlangen, and Nice). Before inclusion,
none of the patients had received any systemic immunosuppressive
treatment. Controls (n¼ 50) included patients with other bullous
diseases and healthy volunteers. Time points for clinical and
immunological assessment were months 0, 1, 3, 6, and 12, and in
case of relapse. Diagnosis of BP was established in each center
based on previously described criteria, and assessment of disease
severity was based on disease activity, disease extent, and pruritus
intensity, which was calculated on a scale ranging from 0 to 8, as
previously described (Di Zenzo et al., 2008). Clinical remission
corresponded to the absence of signs of disease lasting for at least 2
weeks. Complete remission was defined as remission lasting for
more than 3 months without immunosuppressive treatment. Clinical
relapses were defined as the reappearance of clinical symptoms after
the patient had attained remission, adapted from a previously
introduced definition of clinical outcome parameters in pemphigus
(Murrell et al., 2008).
Some patients were followed for o12 months because of loss to
follow-up, withdrawal of consent, or death (Supplementary Table S1
online). However, no differences between subjects with complete or
partial follow-up with respect to age, sex, disease duration, severity,
activity, and itch were observed. Therapeutic regimens were not
defined by the study protocol and the choice of therapy, and dosage
was dependent on disease severity, patient’s conditions, drug
side-effect profile, and the physician’s evaluation. Twenty-four
(69%) BP patients underwent clinical remission during the 1-year
follow-up study. Two BP patients relapsed during the follow-up
period (Supplementary Table S1 online). The study was conducted in
accordance to the Declaration of Helsinki Principles, approved by
the local Ethics Committees of the participating institutions, and all
patients gave written informed consent.
Expression and purification of BP180 and BP230 recombinant
proteins
Previously published recombinants of BP180 and BP230 were
produced and expressed in prokaryotic (E. coli, DH5a) and
eukaryotic (baculovirus-infected Sf21 cells) systems as previously
described (Thoma-Uszynski et al., 2004, 2006; Di Zenzo et al.,
2008). For the production of the shedded BP180 ectodomain,
normal human keratinocytes were grown to subconfluence in a
serum-free medium that was subjected to methanol–chloroform
precipitation. After centrifugation, the pellets were dissolved in
sample buffer for immunoblotting (Di Zenzo et al., 2008).
ELISA and immunoblotting analyses with BP180 and BP230
recombinant proteins
ELISA and immunoblotting analyses were performed as previously
described (Di Zenzo et al., 2008). For detection of IgA reactivity
against LAD-1 protein, extracts prepared as described above were
separated on SDS-PAGE and transferred onto nitrocellulose. The
filter was incubated at first overnight at 4 1C with sera of patients and
controls diluted at 1:20 and then for 90min with an alkaline
phosphatase-linked goat antihuman IgA antibody (Sigma, St Louis,
MO; Di Zenzo et al., 2008). To reduce unspecific variability of IgG
reactivity between different samples, all the sera from a given patient
were run on the same ELISA plate. All extinction data were
standardized based on the positive and negative internal standards,
which were set to 100 and 0 optical density units, respectively, and
termed pemphigoid index value. In addition, to show that ES events
are not due to a random variation of total IgG, the IgG levels of three
representative BP patients were measured (Supplementary Table S3
online) using a human IgG-specific ELISA as previously reported
(Pinna et al., 2009). Certified Reference Material 470 (ERMs-DA470,
Institute for Reference Materials and Measurements, Geel, Belgium)
was used as standard material for human IgG. Probably because of
corticosteroid therapy, IgG levels showed a trend to decrease and
this variation had no effect on the ES data (Supplementary Table S3
online). Of note, the 24 ES events detected in our 35 BP patients
corresponded to an increase of IgG reactivity levels against a given
epitope that was 1-fold, 2-fold, and more than 5-fold in 2, 3, and
19 cases, respectively.
T-cell proliferative assays with BP180 and BP230 recombinants
T-cell proliferative assays were performed as previously described
(Thoma-Uszynski et al., 2006). Briefly, peripheral blood mono-
nuclear cell from BP patients were isolated and plated in triplicate at
105 cells per well in microtiter plates. BP180 and BP230
recombinants were added (10 mgml1), phytohaemagglutinin (1%)
and recombinant glutathione-S-transferase protein (10 mgml1) were
used as controls. After 6 days, each well was pulsed with 0.5 mCi
[3H]thymidine for 12 h, and incorporation was measured. BP180- or
BP230-specific T-cell proliferation was expressed as a stimulation
index, which is the ratio of [3H]thymidine uptake in cultures with
antigen and cultures with glutatnione-S-transferase. Stimulation
index values X2.0 were considered positive.
Statistical analyses
The incidence of ES events was calculated as the ratio of the number
of ES events and the person-months, with the latter calculated under
the hypothesis of uniform occurrence of event and censoring. A 95%
confidence interval has been estimated under Poisson model. The
association of ES (categorized as absent/present) with sex, age of the
studied BP patients (three classes: 60–75, 76–85, and 86þ years),
disease extent, activity, itch, clinical relapse, and mucosal involve-
ment was assessed with w2- test (or Fisher exact test when expected
counts were o5). The association between ES and disease severity
and activity was investigated using non-parametric methods
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(Mann–Whitney) and w2-test, respectively. As for disease activity, BP
patients were grouped into three classes: 0 new blisters (n¼ 16),o3
new blisters (n¼ 8), and X3 new blisters (n¼ 11), and for disease
severity into two classes: 21 patients with disease severity scores
ranging from 2 to 5 and 14 patients with disease severity scores
ranging from 6 to 8. The within-subject relationship between disease
severity in BP patients and level of IgG reactivity during the course of
the disease has been assessed by the Wald test of the coefficient of
fixed-effect regression models, each considering disease severity as
outcome variable and IgG reactivity as independent variable. The
Bonferroni approach was used to take into account multiple
comparison problems. All analyses were performed using Stata
statistical package (StataCorp, 2005).
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